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Abstract
PI3K inhibition in combination with other agents has not been studied in the context of PIK3CA
wild-type, KRAS mutant cancer. In a screen of phospho-kinases, PI3K inhibition of KRAS mutant
colorectal cancer cells activated the MAPK pathway. Combination PI3K/MEK inhibition with
NVP-BKM120 and PD-0325901 induced tumor regression in a mouse model of PIK3CA wild-
type, KRAS mutant colorectal cancer, which was mediated by inhibition of mTORC1, inhibition of
MCL-1, and activation of BIM. These findings implicate mitochondrial-dependent apoptotic
mechanisms as determinants for the efficacy of PI3K/MEK inhibition in the treatment of PIK3CA
wild-type, KRAS mutant cancer.
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1. Introduction
Members of the RAS family of GTPases (HRAS, NRAS, and KRAS) are mutated in
approximately 25% of human cancers, the majority of which are mutations in KRAS, most
commonly KRASG12D [1]. RAS mutations lock RAS into a constitutively activated state,
which promotes tumorigenesis by activating the MAPK signaling pathway even in the
absence of stimulation by receptor tyrosine kinases [2]. Oncogenic mutations in KRAS are
present in 43-51% of colorectal cancers (CRCs), 27-37% of lung adenocarcinomas, and
70-90% of exocrine pancreatic cancers [3–8]. KRAS mutant colorectal and lung
adenocarcinomas are resistant to receptor tyrosine kinase inhibitors [9,10]. Therefore, novel
therapeutic strategies for KRAS mutant cancer are urgently needed.
No inhibitors of KRAS are clinically available despite three decades of efforts. Therefore,
strategies to inhibit KRAS mutant cancers have focused on signaling proteins downstream of
RAS and on parallel signaling pathways such as the phosphoinositide 3-kinase (PI3K)
pathway [11]. Clinical trials of PI3K inhibitors have been limited to patients whose tumors
harbor mutations in PIK3CA, which encodes the p110α subunit of PI3K. However, PIK3CA
mutations are found in only 20-32% of CRCs, 1-4% of lung adenocarcinomas and are not
found in pancreatic cancer; only 8-11% of CRCs are mutant in both PIK3CA and KRAS [3–
6,12–14]. Thus, effective therapies are needed for the approximately 30% of CRCs that are
PIK3CA wild-type, KRAS mutant, as well as for the vast majority of lung and pancreatic
cancers.
We recently reported that inhibition of PI3K and the downstream mammalian target of
rapamycin (mTOR) pathways are effective in a mouse model of PIK3CA wild-type, KRAS
wild-type CRC. However, monotherapy of the PI3K pathway has demonstrated poor clinical
efficacy for KRAS mutant cancer, likely due to adaptive resistance [15]. Here, we use a
phospho-kinase array to rationally identify the MAPK pathway as a resistance mechanism to
PI3K inhibition in KRAS mutant cancer. We then demonstrate that combination PI3K/MEK
inhibition effectively treats a genetically engineered mouse model of PIK3CA wild-type,
KRAS mutant CRC. Finally, we find that PI3K/MEK inhibition effectively blocks mTORC1,
inhibits the BCL-2 anti-apoptotic family member MCL-1, and activates the BH3-only pro-
apoptotic family member BIM. These findings support a role for combination PI3K/MEK
inhibition in the treatment of PIK3CA wild-type, KRAS mutant cancer.
2. Materials and methods
2.1 In vitro treatment of human CRC cell lines
The human colorectal cancer cell lines DLD-1 (KRASG13D, PIK3CAE545K mutant) HCT116
(KRASG13D, PIK3CA H1047R mutant), and SW480 (KRASG13V, PIK3CA wild-type) human
CRC cell lines were obtained from American Type Culture Collection (ATCC). Isogenic
DLD-1 and HCT116 cells have been derived in which either the mutant or wild-type KRAS
allele has been disrupted by targeted homologous recombination [16]. SW480 cells with
shRNA-mediated knockdown of KRAS were obtained as kind gift from D. Chung. Cells
were maintained in DMEM (Invitrogen) with 10% FBS and Penicillin/Streptomycin
(Invitrogen). Cells were plated at different initial densities (HCT116: 3,000 cells/well,
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DLD-1: 5,500 cells/well, and SW480: 4,500 cells/well) to account for differential growth
kinetics. After 16 hours, media was exchanged for DMEM media containing 0.5% FBS and
cells were incubated with increasing concentrations of NVP-BKM120 (Novartis),
PD-0325901 (LC Pharmaceuticals), or a combination [17,18]. Cell viability was assessed 16
hours after the initial plating and 72 hours after initiation of drug treatment using the
colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay
(Promega), as per the manufacturer's instructions. Cell viability after drug treatment was
normalized to that of cells treated with diluent (DMSO) also grown for 72 hours. For
western blot analysis, cells were plated with various concentrations of NVP-BKM120,
PD-0325901, or combination.
2.2 In vitro treatment of murine CRC cell lines
Genetically engineered colorectal tumors were induced in Apcflox/floxKrasG12D/+p53flox/flox
and Apcflox/floxKras+/+p53flox/flox mice [19]. Kras mutant and wild-type immortalized
murine colorectal cancer cell lines were then derived from these tumors, as previously
described [19]. Cell viability was assessed following treatment with NVP-BKM120,
PD-0325901, or combination, as described above.
2.3 Sequencing of colonic tumors from a GEM model of CRC
C57BL/6J Apcflox/floxKrasG12D (Apc-Kras) mice were treated with adenovirus expressing
cre recombinase (University of Iowa), as previously described [20]. Following necropsy, 10
tumor specimens were sequenced for PIK3CA exons nine (helical domain) and 20 (kinase
domain) mutations, as previously described [21].
2.4 In vivo treatment of GEM model of CRC
Apcflox/flox (Apc) and Apc-Kras mice were treated with adenovirus expressing cre
recombinase and followed by optical colonoscopy, as previously described [20]. As a
colonoscopic metric for tumor size, the Tumor Size Index (TSI) was calculated as (tumor
area / colonic lumen area) x 100 (%) [21]. Experimental drugs were diluted in 10% 1-
methyl-2-pyrrolidone/90% PEG 300. Tumor-bearing Apc mice were randomly assigned to
treatment with control vehicle alone (n=8) or 40 mg/kg body weight NVP-BKM120 (n=8)
by daily oral gavage for 7 days. Tumor-bearing Apc-Kras mice were randomly assigned to
treatment with either control vehicle alone, 40 mg/kg body weight NVP-BKM120, 25 mg/kg
PD-0325901, or combination treatment (N=6 per group). No toxicity was observed during
the treatment period. Tumor biopsies were taken before the first treatment and one hour after
the final treatment using biopsy forceps passed through the working channel of the
endoscope sheath (Karl Storz), then flash-frozen in liquid nitrogen for subsequent western
blot analysis [22]. Mice were sacrificed immediately following final biopsy, one hour after
final treatment dose. Tumors were harvested for western blot analysis and
immunohistochemistry. All protocols were approved by the Tufts Institutional Animal Care
and Use Committee.
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2.5 Phospho-kinase analysis
DLD-1 cells treated with or without 500 nM NVP-BKM120 for 24 hours in DMEM media
containing 10% FBS were tested in an array of 43 antibodies against selected
phosphorylated kinases (Proteome Profiler Human Phospho-Kinase Array Kit, R&D
systems), as per the manufacturer's instructions. Phosphorylation of each target was then
quantified using denisitometry (ImageJ).
2.6 Western blot analysis
Cells were seeded into six-well plates, and media was exchanged the following morning for
DMEM containing 0.5% FBS. Cells were harvested at 70% confluency after 72 hours
treatment. Western blot analysis of whole cell and tumor lysates was performed, as
previously described [21]. P-AKTThr308 (1:1000 dilution), AKT (1:1000 dilution) P-
S6Ser240/244 (1:3000 dilution), S6 (1:1000 dilution), P-JNK Thr183/Tyr185(1:1000 dilution),
JNK (1:1000 dilution), cleaved PARP (1:1000 dilution), BIM (1:1000 dilution), and MCL-1
(1:1000 dilution), were obtained from obtained from Cell Signaling Technologies (Beverly,
MA). β-actin (1:5000 dilution) was obtained from Santa Cruz Biotechnology. Secondary
antibody (1:10,000 dilution) was obtained from Jackson ImmunoResearch (West Grove,
PA).
2.7 Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded tissue sections, as previously
described [21]. P-AKTSer473 (1:50 dilution), P-S6Ser240/244 (1:50 dilution) were obtained
from Cell Signaling Technologies (Beverly, MA). Ki-67 (1:100 dilution) was obtained from
US Biological (Swampscott, MA). TUNEL assay (Apoptag) was purchased from Millipore
(Billerica, MA). The Ki-67 staining was quantified as the mean number of Ki-67 positive
cells / total number of glandular cells per high power field (mean of 16 high power fields) ×
100. TUNEL positivity was quantified as mean number of TUNEL positive cells / total
number of glandular cells per high power field (mean of 16 high power fields) × 100.
Measurements were performed by three blinded, independent observers in four control and
four treated tumors.
2.8 Cell cycle analysis
Cells were seeded at roughly 30-40% confluency and treated overnight with the indicated
treatments in DMEM supplemented with 0.5% FBS, or control media, in triplicate. Cells
were collected, washed in PBS, and resuspended in propidium iodide (PI) staining buffer
(PBS containing 1% Triton X-100, 50 mg/ml PI and 50 mg/ml RNase). Cells were incubated
for 30 min (37°C) and DNA content was measured by flow cytometry using a BD
FACSCanto cytometer (BD Biosciences).
2.9 Statistics
Pre- and post-treatment Tumor Size Index values were compared with the Wilcoxon signed-
rank test. All other comparisons between groups were performed using the two-tailed
Student's T test. P<0.05 was considered significant for all analyses. All analyses were
calculated using SPSS 18.0 for Windows (IBM, Inc).
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3. Results
3.1 Human and murine KRAS mutant CRC cell lines are resistant to PI3K inhibition
To assess the efficacy of PI3K blockade in KRAS mutant CRC, we treated CRC cells with or
without KRAS expression with 500 nM NVP-BKM120, a specific inhibitor of all four class I
PI3K isoforms, and assessed cell viability after 72 hours [17]. The dose of 500 nM
NVPBKM120 was selected based on data demonstrating that 500 nM is the IC50 required to
inhibit PI3K activity in vitro [17]. NVP-BKM120 significantly inhibited proliferation of
KRAS wild-type, but not mutant, cell lines (Figure 1A), and suppressed PI3K and
downstream mTORC1 activity in both KRAS wild-type and mutant DLD-1 cells, as assessed
by western blot for P-AKT and P-S6 (Figure 1B). Consistent with a prior report, both
PIK3CA mutant and wild-type cells were sensitive to NVP-BKM120 [17]. We then
confirmed these findings in low passage, immortalized colorectal cancer cell lines derived
from Pik3ca wild-type / Kras wild-type and Pik3ca wild-type / Kras mutant genetically
engineered murine tumors [19]. We found that NVPBKM120 effectively inhibited
proliferation of Pik3ca wild-type / Kras wild-type, but not Kras mutant, murine cell lines
(Figure 1C).
3.2 Genetically engineered Kras mutant murine tumors wild-type for Pik3ca do not
respond to PI3K inhibition
We evaluated the efficacy of PI3K inhibition in genetically engineered mouse models of
PIK3CA wild-type CRC. Consistent with our report that CRC tumors wild-type for Kras and
Pik3ca are sensitive to NVP-BEZ235 (a dual PI3K/mTOR inhibitor), treatment of tumor-
bearing Apc mice with NVP-BKM120 resulted in tumor regression and inhibition of P-AKT
and P-S6 [21] (Figure 1D-F, Supplementary Figure 1). In contrast, treatment of tumor-
bearing Apc-Kras mice had no effect on tumor size but effectively inhibited PI3K and
mTOR activity (Figure 1G-I, Supplementary Figure 2). As expected, 10 of 10 Apc-Kras
tumors tested negative for the most common PIK3CA mutations, H1047R and E545K (data
not shown). These findings suggest that PI3K inhibition is an effective treatment for
PIK3CA wild-type, KRAS wild-type CRC, but does not treat PIK3CA wild-type, KRAS
mutant CRC.
3.3 A phospho-kinase array identifies MAPK activation as a resistance mechanism to PI3K
inhibition
To identify possible resistant mechanisms to PI3K blockade in KRAS mutant CRC, we
assessed the levels of 43 phosphorylated kinases in DLD-1 cells treated with 500 nM and
2500 nM NVPBKM120 relative to vehicle control using a phospho-kinase array (Proteome
Profiler Human Phospho-Kinase Array Kit, R&D systems) (Figure 2A). 500 nM NVM-
BKM120 treatment resulted in activation of P-JNKThr183/Tyr185, Thr221/Tyr223 (54%), P-
mTORSer2448 (50%), P-ERK1/2Thr202/Tyr204, Thr185/Tyr187 (32%), P-SRCTyr419 (20%), and
P-MEK1/2Ser218/Ser222, Ser222/Ser226 (17%) (Supplementary Table 1). SRC and mTOR are
well-established molecular pathways in KRAS wild-type CRC [23,24]. We therefore selected
the JNK and MAPK pathway (which includes ERK and MEK) as candidate resistance
mechanisms to PI3K inhibition.
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We first sought to validate the findings from the phospho-kinase array with western blot to
identify resistance mechanisms to PI3K inhibition that are specific to KRAS mutant cancer.
Treatment of KRAS wild-type, but not KRAS mutant, isogenic DLD-1 cells with 1500 nM
NVPBKM120 resulted in activation of P-JNK. This is consistent with evidence that JNK
plays an important role in tumor progression in an Apc mutant, Kras wild-type mouse model
of intestinal tumorigenesis [25]. In contrast, treatment of KRAS mutant DLD-1 cells and
Apc-Kras tumors resulted in greater P-ERK1/2 and P-MEK activation compared to
treatment of their KRAS wild-type counterparts (Figures 2B-2E, Figure 2C, Supplementary
Figures 1 and 2). We therefore identified the MAPK pathway as a likely resistance
mechanism to PI3K blockade in KRAS-mutant CRC.
3.4 Dual PI3K/MEK inhibition overcomes PI3K resistance in KRAS mutant human and
murine CRC cells
To assess the role of dual PI3K/MEK blockade in treatment of KRAS mutant CRC, we
treated KRAS wild-type and mutant CRC cells with 500 nM NVP-BKM120, 100 nM of the
specific MEK inhibitor PD-0325901, or combination, and assessed cell viability [18]. For all
three sets of cell lines, combination therapy was significantly more effective than
monotherapy in inhibiting cellular proliferation in KRAS mutant cells (Figures 2D-2G).
Corresponding western blot analysis for DLD-1 isogenic lines demonstrated elevated
baseline P-ERK1/2 levels in KRAS-mutant lines, activation of P-ERK with NVP-BKM120
treatment, and maximal inhibition of PAKT and P-S6 with combination PI3K/MAPK
inhibition (Figure 2E). Analogous experiments in Kras wild-type and mutant murine CRC
cell lines demonstrated greater efficacy with combination therapy compared to NVP-
BKM120 or PD-0325901 monotherapy (Figure 2H).
3.5 Combination PI3K/MEK inhibition induces tumor regression and inhibits proliferation
in Pik3ca wild-type, Kras mutant murine colorectal tumors
We then sought to validate our in vitro findings in the genetically engineered mouse model
of CRC. We treated Apc-Kras tumors with NVP-BKM120, PD-0325901, or combination,
for seven days, and assessed tumor size and activation of the PI3K, mTOR, and MAPK
pathways before and after treatment. Combination PI3K/MEK therapy was required for
maximal tumor regression in Apc-Kras tumors and inhibition of the PI3K, mTORC1, and
MAPK pathways (Figure 3A-C, Supplementary Figure 2). Immunohistochemistry for Ki-67
revealed that while NVP-BKM120 was sufficient for inhibition of tumor cell proliferation in
Apc tumors, combination NVPBKM120 / PD-0325901 was required for inhibition of
proliferation in Apc-Kras tumors (Figure 4A-D).
3.6 Dual PI3K/MEK inhibition induces G1 phase arrest in KRAS mutant CRC cell lines
To further explore the mechanisms by which PI3K/MEK inhibition treats KRAS mutant
CRC, we assessed cell cycle progression in DLD-1 and HCT116 KRAS isogenic cell lines.
For both lines, NVP-BKM120 or PD-0325901 monotherapy was sufficient to induce G1
phase arrest in KRAS wild-type cells, while combination NVP-BKM120 / PD-0325901
treatment was required to induce G1 phase arrest in KRAS mutant cells (Supplementary
Figure 3).
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3.7 Combination PI3K/MEK blockade activates apoptotic pathways and inhibits anti-
apoptotic pathways in KRAS mutant CRC
Based on our finding that PI3K/MEK treatment blocks cell proliferation by inducing cell
cycle arrest, we asked whether combination treatment promotes apoptosis. In KRAS wild-
type isogenic cells, NVP-BKM120 therapy was sufficient to induce cleavage of PARP by
Caspase 3, a marker of cellular apoptosis. However, in KRAS mutant isogenic cells,
combination NVP-BKM120 / PD-0325901 treatment was required to induce PARP cleavage
(Figure 5A-B). In vivo, while PI3K blockade induced apoptosis in Apc tumors, combination
PI3K/MEK inhibition was required to induce apoptosis in Apc-Kras tumors (Figure 5C-F).
MCL-1 is one of the most highly amplified genes in human cancers, particularly colorectal
cancer [26]. MCL-1 is a member of the BCL-2 family of anti-apoptotic proteins and acts on
the mitochondrial membrane to directly bind and sequester BH3-only pro-apoptotic family
members such as BIM [27]. We therefore asked whether the efficacy of combination
PI3K/MEK inhibition in KRAS mutant CRC is in part due to inhibition of MCL-1 and/or
activation of BIM. We found that NVP-BKM120 or PD-0325901 was sufficient to inhibit
MCL1 and activate BIM in KRAS wild-type CRC cell lines and genetically engineered
colorectal tumors, while combination therapy was required to achieve the same apoptotic
effect in KRAS mutant CRC cell lines and tumors (Figure 6).
4. Discussion
Therapeutic options for cancers with activating mutations in KRAS are limited. A number of
studies have identified unbiased strategies to treat KRAS mutant cancers through RNA
interference screens, including inhibition of TAK1, STK33, TBK1, WT1, GATA2, and
BCL-XL / MEK [28–33]. However, follow up studies have been difficult to reproduce,
possibly due to the off-target effects of RNA interference [34]. Moreover, clinical
translation of these findings is limited by the need for selective, efficacious, and nontoxic
drugs that target these pathways. In this study, we used a phospho-kinase array to identify
adaptive mechanisms of resistance to PI3K inhibition in KRAS mutant CRC cells among 43
well-characterized kinases, most of which are targeted by known selective agents. This
analysis revealed many potential phosphorylated mediators of PI3K resistance, including
JNK, mTOR, ERK, MEK, SRC, p38a, HCK, p27, and FYN. The MAPK pathway has
gained the most extensive interest as a resistance mechanism to PI3K inhibition due to
multiple nodes of cross-talk between these pathways and the broad availability of selective
pre-clinical therapeutics [35].
The importance of MAPK signaling in adaptive resistance to selective pan-class I PI3K
inhibitors is supported by several studies demonstrating the combined benefit of PI3K/MEK
inhibition in the treatment of PIK3CA mutant, KRAS mutant colorectal, ovarian, and lung
cancers [36–42]. However, these studies did not examine the role of PI3K/MEK inhibition
in PIK3CA wild-type cancers, which comprise the majority of KRAS-mutant cancers [3].
Despite studies suggesting that PI3K inhibitors are somewhat more effective in cancers with
mutations in PIK3CA, we previously found that PIK3CA isogenic CRC cell lines and
PIK3CA wild-type murine colorectal tumors are sensitive to PI3K/mTOR inhibition due to
constitutive AKT activity [17,21,43]. Here, we show that combination PI3K/MEK inhibition
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is effective in inducing regression of PIK3CA wild-type, KRAS mutant CRC by inhibiting
mTORC1, blocking the anti-apoptotic activity of MCL-1 and increasing the pro-apoptotic
activity of BIM.
In vivo studies of PI3K/MEK inhibition have largely depended on 1) human cell lines and
xenografts in immune-compromised mice that fail to recapitulate the complex host-stroma
interaction in human tumors, or 2) genetic manipulations to over-activate PI3K in mouse
models that are not commonly found in the cancer of study [37,38,41]. To avoid these
limitations, we first tested our hypothesis in PIK3CA mutant (DLD-1 and HCT116) and
wild-type (SW480) KRAS mutant human CRC cell lines. We then confirmed our findings in
our Pik3ca wild-type murine CRC cell lines that are Kras mutant or Kras wild-type. These
murine tumor-derived CRC cell lines are an excellent preclinical resource for drug
discovery; they are genetically defined, recently derived (<5 passages), and recapitulate key
genetic signatures of KRAS mutant and wild-type human cancers [19].
We validated our in vitro findings in genetically engineered mouse models of PIK3CA wild-
type, KRAS wild-type (Apc) or PIK3CA wild-type, KRAS mutant (Apc-Kras) CRC. These
models reproduce important features of human CRC: 1) tumors derive from somatic
modification of driver genes such as Apc; 2) tumors recapitulate the adenoma-carcinoma-
metastasis sequence; 3) only 1-3 tumors form; and 4) tumors are located only in the colon
[20]. We have previously demonstrated the utility of endoscopic monitoring to assess tumor
size before and after treatment [20,21,44]. Here, we show that tumors can be biopsied before
and after drug therapy to assess mechanisms of response and resistance in individual mice.
Taken together, our rigorous three-step approach (e.g., human cell line, murine cell line, and
genetically engineered mouse model studies) represents a new model for preclinical
therapeutic studies that maximizes the likelihood of translational relevance.
Our findings are relevant to the clinical care of patients with KRAS-mutant cancers for a
number of reasons. First, although a number of Phase I clinical trials are currently
examining the role of PI3K/MEK blockade in KRAS-mutant CRC and other cancers, patients
harboring PIK3CA wild-type cancers are currently excluded [35]. Our findings suggest that
the scope of these studies should be expanded to include PIK3CA wild-type patients.
Second, our finding that tumor regression with combination PI3K/MEK therapy in KRAS-
mutant CRC was associated with mTORC1 inhibition corroborates recent reports that
mTORC1 suppression predicts sensitivity to MEK [45] or PI3K [46] inhibition. Together,
these reports and our work suggest that efficacy of PI3K and MEK inhibitors as
monotherapy or in combination depend on mTORC1 blockade. Finally, we report that
modulation of the mitochondrial-dependent apoptotic program is an important mechanism
for the effectiveness of PI3K/MEK inhibition. Previous studies have identified the anti-
apoptotic BCL-2 family member MCL-1 and the pro-apoptotic BH3-only family member
BIM as sentinel effectors in cancer cell apoptosis in response to targeted therapy [40,47–50].
Our results therefore support future studies on BCL-2 family inhibitors in KRAS mutant
cancer.
Our findings raise the question of whether combination PI3K/MEK inhibition may be
beneficial to patients harboring KRAS wild-type cancers. Prior reports have demonstrated
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that KRAS wild-type cells are less sensitive to MEK inhibition than KRAS-mutant cells
[37,42]. However, we found that DLD-1 KRAS wild-type cells, and one of two Kras wild-
type CRC tumors, exhibited modest induction of P-ERK following treatment with PI3K
inhibitor (Figures 2C and 2E). While KRAS wild-type cells were exquisitely sensitive to
PI3K inhibition alone, combination treatment with a MEK inhibitor provided additional
reduction in cell viability, induction of BIM, and inhibition of MCL-1 (Figures 2D, 2F-2H,
and 6A) without increased cell cycle arrest or PARP cleavage (Supplementary Figure 1,
Figures 5A-5B). Thus, our findings implicate a potential role for combination PI3K/MEK
inhibition in KRAS wild-type cancer. Taken together, further studies are needed to explore
this therapeutic paradigm.
In conclusion, we report the efficacy of combination PI3K/MEK inhibition of PIK3CA wild-
type, KRAS-mutant human CRC cell lines, mouse CRC cell lines, and genetically engineered
mice. Tumor regression with dual PI3K/MEK therapy was mediated by mTORC1 inhibition,
MCL-1 inhibition, and BIM up-regulation. Our findings provide a rationale for testing
PI3K/MEK inhibitors in patients with PIK3CA wild-type, KRAS-mutant cancer.
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Figure 1. KRAS mutant CRC is resistant to PI3K inhibition
(A) KRAS mutant CRC cell lines DLD-1 and HCT116 and their wild-type isogenic
counterparts and SW480 control or sh-KRAS cells were seeded in 0.5% FBS media, then
treated with DMSO (-) or 500 nM NVPBKM120 (+) for 72 hours. Cell viability was
assessed via MTS assay. (B) PI3K (P-AKTThr308) and mTORC1 (P-S6Ser240/244) activity in
DLD-1 KRAS wild-type and mutant isogenic cells was assessed via western blot. (C)
Kras+/+ (F62 and E75) and KrasG12D/+ (a54 and a88) murine CRC cell lines were seeded in
0.5% FBS media, then treated with DMSO (-) or 500 nM NVPBKM120 (+) for 72 hours.
Proliferation was assessed via MTS assay. Tumor-bearing Apcflox/flox (Apc) mice were
randomized to vehicle or 40 mg/kg NVP-BKM120 for seven days. Colonoscopy images (D)
were taken before and after treatment to calculate Tumor Size Index (tumor area / luminal
area x 100) (E). Tumor biopsies were obtained before and after treatment and assayed for
PI3K and mTORC1 signaling via western blot (F). Similar experiments were performed in
Apcflox/flox / KrasG12D/+ (Apc-Kras) mice (G-I). *P<0.01.
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Figure 2. PI3K blockade induces MAPK activation in KRAS mutant CRC and is overcome with
combination PI3K/MEK inhibition
(A) DLD-1 cells were treated with DMSO, 500 nM NVP-BKM120, or 2000 nM NVP-
BKM120 for 24 hours. Cell lysates were probed with a phospho-kinase array (Proteome
Profiler Human Phospho-Kinase Array Kit, R&D systems). (PERK1/2Thr202/Tyr204, red
boxes) (B) DLD-1 KRAS WT and mutant isogenic cells were treated with 2000 nM
BKM120 for 72 hours, and probed for JNK and MAPK signaling with western blot. (C)
Tumor biopsies from two Apc and Apc-Kras mice before and after 7 days treatment with
vehicle or NVP-BKM120 were assessed for P-ERK1/2 Thr202/Tyr204 signaling with western
blot. DLD-1 (D), HCT116 (F), SW480 (G), and murine (H) KRAS WT and mutant cells
were treated with DMSO, 500 nM NVP-BKM120, 100 nM PD325901, or combination for
72 hours. Cell viability was assessed via MTS assay. (E) KRAS WT and mutant isogenic
DLD-1 cells were treated for 72 hours with DMSO, 500 nM NVP-BKM120 (+), or 2000 nM
NVP-BKM120 (++), with or without 100 nM PD325901, then probed for MAPK (P-
ERK1/2Thr202/Tyr204), mTORC1 (P-S6Ser240/244), and PI3K (P-AKTThr308) signaling.
*P<0.001.
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Figure 3. Combination PI3K/MEK inhibition induces tumor regression in a mouse model of
PIK3CA wild-type, KRAS-mutant CRC
Tumor-bearing Apc-Kras mice were treated with vehicle, 40 mg/kg NVP-BKM120, 25
mg/kg PD-325901, or combination for seven days. (A) Representative colonoscopic tumor
images are shown before and after treatment. (B) Tumor size index (tumor area / luminal
area x 100) was assessed for each tumor before and after treatment to calculate percent
change in tumor size. (C) Biopsy specimens obtained before and after treatment for two
tumors in each treatment group were probed for PI3K, mTORC1, and MAPK signaling with
western blot.
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Figure 4. Dual PI3K/MEK inhibition inhibits proliferation of Kras-mutant CRC in vivo
Tumor-bearing Apc mice were treated with control or NVP-BKM120 for seven days. After
sacrifice, Ki-67 staining of tumors was assessed by immunohistochemistry (20X) (A-B).
Tumor-bearing Apc-Kras mice were treated with control, NVP-BKM120, PD-325901, or
combination for seven days. Ki-67 staining of tumors was assessed by
immunohistochemistry (20X) (C-D). *P<0.01.
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Figure 5. Combination PI3K/MEK inhibition is required for induction of apoptosis in KRAS
mutant CRC
Isogenic KRAS mutant and wild-type DLD-1 (A) and HCT116 (B) CRC cells were treated
with DMSO, 500 nM NVP-BKM120, 100 nM PD325901, or combination for 72 hours. Cell
lysates were probed for Cleaved PARP. (C-F) Control and treated Apc and Apc-Kras tumor
specimens were assessed for TUNEL staining (20X). *P<0.01.
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Figure 6. Dual PI3K/MEK blockade promotes apoptosis by inhibiting MCL-1 and activating
BIM in KRAS mutant CRC
(A) Isogenic DLD-1 KRAS wild-type and mutant cells were treated with DMSO, 500 nM
NVP-BKM120, 100 nM PD-325901, or combination for 72 hours. Cell lysates were
assessed for BIM and MCL-1 expression. (B) Tumor biopsies from Apc and Apc-Kras mice
before and after treatment with vehicle, NVP-BKM120, or PD-325901 were assessed for
BIM and MCL-1 expression.
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